Congenital adrenal hyperplasia (CAH ... “CAH is a form of primary adrenal insufficiency in which cortisol production is decreased or completely absent,” Kyriakie Sarafoglou, MD, professor ...

WASHINGTON, D.C. — The U.S. Food and Drug Administration (FDA) has approved Crenessity (crinecerfont) for use alongside glucocorticoids in managing classic congenital adrenal hyperplasia (CAH ...

CAH differs from adrenal insufficiency in that because of the ... Fechner, MD, is medical director of Seattle Children’s Congenital Adrenal Hyperplasia Center and professor of pediatrics at ...

Glucocorticoid-induced adrenal insufficiency was lower in prevalence than previously estimated among patients with PMR or GCA.

for paediatric adrenal insufficiency and Efmody (hydrocortisone modified-release hard capsules) for congenital adrenal hyperplasia (CAH) – to Neurocrine's commercial portfolio. In July ...

Research in the Centre for Endocrinology under the leadership of Professor Louise Metherell has greatly improved diagnosis and understanding of Adrenal Insufficiency ... MAPK pathway components cause ...